Back to Condition
CLN1 disease
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

CLN1 disease

CLN1 disease is an inherited disorder that primarily affects the nervous system, leading to developmental regression, seizures, and vision loss.

Overview

CLN1 disease is an inherited disorder that primarily affects the nervous system. Individuals with this condition typically have normal development in infancy, but by 18 months, they often become increasingly irritable and begin to lose previously acquired skills, a process known as developmental regression. Over time, brain cells die, leading to brain atrophy and an unusually small head. Affected children typically experience hypotonia (decreased muscle tone), intellectual and motor disability, and rarely gain the ability to speak or walk.

Symptoms

Symptoms often progress as the disease worsens. Common clinical features include:

  • Developmental regression
  • Irritability
  • Hypotonia
  • Repetitive hand movements
  • Myoclonus (muscle twitches)
  • Epilepsy (recurrent seizures)
  • Vision loss
  • Frequent respiratory infections
  • Severe feeding difficulties, often requiring a feeding tube

In later-onset cases, which may manifest in childhood or adulthood, individuals experience a decline in intellectual function, myoclonus, epilepsy, and vision loss. Adults may also exhibit movement disorders, such as ataxia (impaired muscle coordination) or parkinsonism.

Causes

CLN1 disease is caused by mutations in the PPT1 gene, which provides instructions for making an enzyme called palmitoyl-protein thioesterase 1. This enzyme is active in lysosomes, the cell compartments responsible for digesting and recycling molecules. The enzyme removes long-chain fatty acids from certain proteins to facilitate their breakdown. Mutations in PPT1 decrease or eliminate the function of this enzyme, causing partially broken-down fats and proteins to accumulate in lysosomes, which is particularly damaging to nerve cells.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene but typically do not show signs or symptoms of the condition.

Frequently Asked Questions

Parents should monitor for sudden loss of previously mastered skills such as sitting, crawling, or babbling, especially between 12 and 24 months. A noticeable increase in irritability, a decline in muscle tone (hypotonia), and the appearance of repetitive hand movements or mild muscle twitches (myoclonus) are also early red flags that warrant prompt evaluation by a pediatric neurologist. How are seizures typically managed in children with CLN1, and are newer antiepileptic drugs useful?::Seizure control in CLN1 often requires a combination of antiepileptic drugs (AEDs) such as levetiracetam, valproate, or clobazam. Newer AEDs like cannabidiol (CBD) or perampanel have shown promise in reducing seizure frequency in some patients, but their effectiveness varies. A specialist will tailor therapy based on seizure type, frequency, and side‑effect profile, and may adjust doses as the disease progresses. When is it appropriate to consider a feeding tube for a child with CLN1, and what are the main risks and benefits?::A feeding tube is usually considered when the child experiences severe feeding difficulties, frequent aspiration, or cannot maintain adequate weight gain despite oral nutrition. Benefits include improved nutrition, reduced choking risk, and better overall growth. Risks involve infection at the insertion site, tube displacement, and the need for ongoing care. A multidisciplinary team—including a pediatric gastroenterologist, dietitian, and speech‑language pathologist—should evaluate the timing and type of tube (nasogastric vs. gastrostomy). Are there any clinical trials or gene‑therapy options available for CLN1 disease, and how can I find out if my child is eligible?::Several research groups are investigating gene‑replacement therapy using viral vectors to deliver functional PPT1 to the brain, as well as substrate‑reduction strategies. Eligibility depends on age, disease stage, and genetic confirmation. Parents can contact the National Institute of Neurological Disorders and Stroke (NINDS) or the Rare Diseases Clinical Research Network (RDCRN) for up-to-date trial listings, or consult a metabolic or lysosomal storage disorder specialist for referral to a clinical trial center.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab